FTC And Amgen Reach Agreement On Horizon Therapeutics Deal
As per the US Federal Trade Commission (FTC), Amgen is prohibited from using its drug portfolio to unfairly disadvantage its competitors in the industry. The biopharmaceutical company will need to obtain prior approval before acquiring related products. The FTC has agreed with Amgen Inc. to address the potential harm to competition that could arise from […]
The Medicines Manufacturing Skills Initiative By The UK
The UK government dedicates £5.5 million towards establishing a Medicines Manufacturing Skills Centre of Excellence. This center aims to bolster the pool of skilled individuals in the UK’s life sciences sector, fostering innovation and enabling the country to respond to future health crises effectively. It will leverage existing infrastructure and industry best practices to provide […]
Syntegon at CPHI Barcelona: new solutions for small and micro batches
At CPHI Barcelona 2023, Syntegon will showcase new developments for the filling and processing of small and micro batches. Equipment designed specifically for small batch sizes is in high demand not only for research and development, but also for the commercial production of liquid and solid pharmaceuticals. Visitors to booth 3S50 will see two innovations […]
Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech, River BioMedics, receives an additional €2M seed investment
Sygnature Discovery (Sygnature) is delighted to announce that its customer, River BioMedics, has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. Libertatis Ergo Holding, an independent subsidiary of Leiden University joins the investment syndicate alongside further investment from existing investors FIRST fund, managed by BioGeneration Ventures (BGV), KIKK Capital […]
ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant
ST Pharm said it has taken its first step towards becoming the global leader in the oligonucleotide contract development and manufacturing organization (CDMO) domain with the groundbreaking ceremony for its second oligonucleotide facility. The new plant will be located in Ansan, Gyeonggi Province. The company has planned an initial investment of 1.1 trillion won ($830.9 million) […]
Management change at Syntegon Group: Michael Grosse to hand over CEO role to Torsten Türling
Torsten Türling becomes new CEO of Syntegon Group effective as of November 1, 2023 Michael Grosse resigns as of October 31, 2023 Waiblingen (Germany), September 21, 2023. The Syntegon Group, a globally leading provider of processing and packaging technology, appoints Torsten Türling as new Chief Executive Officer (CEO). He succeeds Dr. Michael Grosse, who will […]
Accelerating Drug Development Through CDMO Partnerships
Based on current market analyses, global pharmaceutical spending is projected to reach approximately $1,742 billion by 2025. Concurrently, spending on COVID-19 vaccines and therapeutics is anticipated to reach around $53 billion worldwide in the same year. Two predominant trends currently shaping the pharmaceutical market are: firstly, there is a notable upsurge in innovative drugs offering […]
Prefilled Syringes Market Surges To $18.43 Billion In 2023
The global market for prefilled syringes reached a value of USD 18.43 billion in 2023 and is expected to experience a compound annual growth rate (CAGR) of 11.95% from 2023 to 2030. This growth is primarily fueled by the increasing demand for user-friendly drug delivery devices and the healthcare sector’s efforts to reduce errors in […]
Takeda Reiterates the Need of Equitable Access to Healthcare for Universal Impact
Takeda Biopharmaceuticals India Private Limited (formerly Baxalta Bioscience India Pvt Ltd) – a global values-based, R&D-driven biopharmaceutical leader in innovative healthcare solutions presented an industry perspective on equitable access to healthcare during the 5th edition of the Confederation of Indian Industry (CII) UP Health Summit “Empowering Wellness: Transforming Lives for a Healthy Future”. The summit […]
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
Samsung Biologics announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. Under the terms of the new agreement, […]
